We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Get help to classify herbal medicines, vitamins, food preparations, supplements and tonics for import and export.
Competent authorities of exporting countries should use the relevant model health certificate as a template to create a version exporters can apply for to export fats to Great Britain, the Channel Islands or Isle of Man.
How businesses and organisations can avoid causing pollution from oil and chemical storage, car washing, construction and other activities.
Find out which types of food are zero-rated and which are standard-rated for VAT purposes.
Information about regulations restricting the advertising and promotion of less healthy food or drink, also known as foods high in fat, salt or sugar.
Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.
Anyone who suspects that they’ve had an adverse reaction to their weight loss or diabetes medicine or suspects it is not a genuine product, should report it to the MHRA.
Outlines the provisions of the Food (Promotion and Placement) (England) Regulations 2021, and provides assistance in understanding and applying them.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with the menopause.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).